May 06, 2022 (PRNewswire via COMTEX) -- PR Newswire
BOSTON, May 6, 2022
BOSTON, May 6, 2022 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. /zigman2/quotes/207284462/composite NRBO +2.26% , a clinical-stage biotechnology company, today announced the appointment, effective April 30, 2022 of Matthew Bardin, PharmD, BCPS as Senior Vice President, Operations. Reporting directly to President and Chief Executive Officer, Gil Price, M.D., Dr. Bardin will be responsible for day to day operations, with a focus on clinical development.
"Matthew is a highly experienced pharmaceutical professional who brings to NeuroBo an extensive track record of clinical drug development, medical affairs and oversight expertise in a number of therapeutic areas, most importantly within the area of infectious diseases and gastroenterology," stated Gil Price, M.D., President and Chief Executive Officer of NeuroBo. "We are excited to welcome Matthew to our team, especially as we continue to advance our lead drug candidate, ANA001, and continue to identify new products for licensure and development."
Prior to joining NeuroBo, Dr. Bardin held positions of increasing responsibility at Romark, L.C., a vertically integrated, research-based pharmaceutical company focused primarily on gastroenterology and infectious diseases, where he most recently served as Vice President, Medical Affairs/Research and Development. During his tenure at Romark, Dr. Bardin was responsible for all clinical drug development, medical affairs activities, and pharmacovigilance oversight for the company. Before that, Dr. Bardin was with Clinical Pharmacology Services, Inc./Conexus Health, a company dedicated to improving medication use, patient safety and health outcomes, last holding the position of Clinical Services Manager. Earlier in his career, Dr. Bardin was a Pharmacy Clinical Coordinator at South Florida Baptist Hospital and was a Pharmacy Practice Resident at Piedmont Hospital, in Atlanta, GA.
Dr. Bardin is the co-author of numerous publications and abstracts in the area of gastroenterology and infectious diseases. He earned a Doctor of Pharmacy degree from Samford University McWhorter School of Pharmacy, Birmingham, AL and a Bachelor of Science, Biochemistry from Florida State University in Tallahassee, FL. He is a Certified MedDRA Coder, a Board Certified Pharmacotherapy Specialist and holds both a Florida Pharmacist and Florida Consultant Pharmacist License.
Forward Looking Statements Any statements in this press release that are not statements of historical fact constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to, statements regarding NeuroBo's development expenses, the development of NeuroBo's product candidates and the therapeutic potential, timing and nature of clinical trials and potential regulatory approval of NeuroBo's clinical programs and pipeline. Forward-looking statements are usually identified by the use of words, such as "believes," "anticipates," "expects," "intends," "plans," "may," "potential," "will," "could" and similar expressions. Actual results may differ materially from those indicated by forward-looking statements as a result of various important factors and risks. These factors, risks and uncertainties include, but are not limited to: recent changes in NeuroBo's management; the failure to obtain all of the benefits or recognize all of the synergies anticipated from the ANA acquisition; the integration of ANA potentially diverting management resources from operational matters and other strategic opportunities; the effect of future milestone payments and royalties specified in the ANA acquisition agreement on the results of operations and financial position of NeuroBo; the occurrence of health epidemics or contagious diseases, such as COVID-19, and potential effects on NeuroBo's business, clinical trial sites, supply chain and manufacturing facilities; NeuroBo's ability to continue as a going concern; the timing of completion of NeuroBo's planned clinical trials, including with respect to ANA001 and Gemcabene; the timing of the availability of data from NeuroBo's clinical trials, including with respect to ANA001 and Gemcabene; NeuroBo's plans to research, develop and commercialize its current and future product candidates, including the potential alternative pathways for NB-01; NeuroBo's ability to successfully collaborate with existing collaborators or enter into new collaborations and to fulfill its obligations under any such collaboration agreements; the clinical utility, potential benefits and market acceptance of NeuroBo's product candidates, including ANA001 and Gemcabene; the impact of government laws and regulations; NeuroBo's ability to protect its intellectual property position; and NeuroBo's need for additional financing to fulfill its stated goals. Please refer to NeuroBo's most recent annual report on Form 10-K, as well as NeuroBo's subsequent filings on Form 10-Q and Form 8-K, which are available on the SEC's website ( www.sec.gov ), for a full discussion of the risks and other factors that may impact any forward-looking statements in this press release. In addition, the forward-looking statements included in this press release represent NeuroBo's views as of the date hereof. NeuroBo anticipates that subsequent events and developments will cause its views to change. However, while NeuroBo may elect to update these forward-looking statements at some point in the future, NeuroBo specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing NeuroBo's views as of any date subsequent to the date hereof.
Rx Communications Group
SOURCE NeuroBo Pharmaceuticals, Inc.
Is there a problem with this press release? Contact the source provider Comtex at firstname.lastname@example.org. You can also contact MarketWatch Customer Service via our Customer Center.
Copyright (C) 2022 PR Newswire. All rights reserved